Compare · PMCB vs VCEL
PMCB vs VCEL
Side-by-side comparison of PharmaCyte Biotech Inc. (PMCB) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PMCB and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- VCEL is the larger of the two at $2.93B, about 687.3x PMCB ($4.3M).
- VCEL has been more active in the news (11 items in the past 4 weeks vs 1 for PMCB).
- VCEL has more recent analyst coverage (11 ratings vs 1 for PMCB).
- Company
- PharmaCyte Biotech Inc.
- Vericel Corporation
- Price
- -
- -
- Market cap
- $4.3M
- $2.93B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 1
- 11
- Recent ratings
- 1
- 11
PharmaCyte Biotech Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest PMCB
- PharmaCyte Biotech, Inc. Announces Reverse Stock Split
- SEC Form 8-K filed by PharmaCyte Biotech Inc.
- SEC Form 10-Q filed by PharmaCyte Biotech Inc.
- SEC Form 10-K filed by PharmaCyte Biotech Inc.
- Amendment: SEC Form 4 filed by Director Weinstein Robert
- Amendment: SEC Form 4 filed by Director Walker Wayne Remell
- Amendment: SEC Form 4 filed by Director Abecassis Michael M
- Amendment: SEC Form 4 filed by Director Schechter Jonathan
- SEC Form 4 filed by Walker Wayne Remell
- SEC Form 4 filed by Weinstein Robert
Latest VCEL
- Chief Financial Officer Mara Joseph Anthony Jr exercised 25,008 shares at a strike of $43.63 and sold $1,456,978 worth of shares (25,008 units at $58.26) as part of a pre-agreed trading plan (SEC Form 4)
- Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $13.05 and sold $412,720 worth of shares (7,000 units at $58.96) as part of a pre-agreed trading plan (SEC Form 4)
- Director Zerbe Robert L Md exercised 2,000 shares at a strike of $13.05 and sold $115,760 worth of shares (2,000 units at $57.88) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr exercised 50,000 shares at a strike of $32.36 and sold $2,674,019 worth of shares (50,000 units at $53.48) as part of a pre-agreed trading plan (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan exercised 1,500 shares at a strike of $34.90 and sold $79,350 worth of shares (1,500 units at $52.90) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Flynn Sean C. exercised 15,000 shares at a strike of $16.25 and sold $778,800 worth of shares (15,000 units at $51.92) as part of a pre-agreed trading plan (SEC Form 4)
- Director Zerbe Robert L Md exercised 5,500 shares at a strike of $13.05 and sold $270,175 worth of shares (5,500 units at $49.12) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance